⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 23, 2013Journal of Clinical OncologyOpen Access

Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma

Pritesh S. Karia Anokhi Jambusaria‐Pahlajani David P. Harrington Gëorge F. Murphy Abrar A. Qureshi Chrysalyne D. Schmults

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

BWH staging offers improved distinctiveness, homogeneity, and monotonicity over AJCC and UICC staging. Population-based validation is needed. BWH T2b/T3 tumors define a high-risk group requiring further study for optimal management.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Karia et al. (2013) studied this question.

synapsesocial.com/papers/69d9a7011ad561c673684def https://doi.org/10.1200/jco.2012.48.5326

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Stereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non–Small Lung Cancer: An Emulated Target TrialJournal of Clinical Oncology · 2026
2Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled TrialJournal of Clinical Oncology · 2026
3Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical TrialJournal of Clinical Oncology · 2026
4Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026
5KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026

Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 StudyJournal of Clinical Oncology · 2026
Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from Harvard University

More from Brigham and Women's Hospital